Allogeneic and Autologous Anti-CD7 CAR-T Cell Therapies in Relapsed or Refractory T Cell Malignancies

医学 氟达拉滨 细胞因子释放综合征 全血细胞减少症 环磷酰胺 胃肠病学 移植物抗宿主病 内科学 T细胞 外周血单个核细胞 嵌合抗原受体 免疫学 移植 外科 免疫系统 化疗 骨髓 生物化学 化学 体外
作者
Yinqiang Zhang,Chenggong Li,Huanhuan Jiang,Wenjing Luo,Mengyi Du,Fen Zhou,Lu Tang,Jianghua Wu,Qi Wei,Cong Lu,Haiming Kou,Di Wu,Chang Alex H,Heng Mei,Yu Hu
出处
期刊:Blood [American Society of Hematology]
卷期号:140 (Supplement 1): 4592-4594 被引量:2
标识
DOI:10.1182/blood-2022-170819
摘要

Aims To evaluate the safety and efficacy of anti-CD7 chimeric antigen receptor-T (CAR-T) therapies in teenagers and adult patients with relapsed/refractory (R/R) T cell malignancies, as well as differences between autologous and allogeneic CAR-T cells. Methods This Phase I, single-arm, open-label clinical trial (NCT04823091) enrolled patients with R/R T-Cell Acute Lymphoblastic Leukemia (T-ALL)/ Lymphoblastic Lymphoma (LBL) (aged 14-70 years). Patients underwent lymphodepletion with fludarabine and cyclophosphamide followed by CAR-T infusion at a dose of 1x106 or 2x106/kg on D0. CAR-T cells were manufactured either from patients or donors, based primarily on the patient's tumor burden, pancytopenia status, donor availability and the wishes of the patient. Donors could be 5/10 HLA-identical siblings or 10/10 HLA-matched. Bridging therapies were allowed if disease progressed between infusion and the collection of peripheral blood mononuclear cells (PBMCs). Results From June 2021 to July 2022, 10 patients aged 14 to 69 with T-ALL (N=3) and T-LBL (N=7) were treated with anti-CD7 CAR-T cells. Five patients received autologous CAR-T cells and five received allogeneic CAR-T cells. Seven patients experienced grade ≤2 cytokine release syndrome (CRS) and one developed grade 3 CRS. The median onset and duration of CRS was 10 days and 4 days, respectively. Immune effector cell-associated neurotoxicity syndrome was not observed. Grade 1-2 graft versus host disease(GVHD)occurred in two patients. Patient (PT) 4 who receive allogeneic CAR-T developed acute GVHD presenting as diarrhea and maculopapular rash. PT2 with previous allogeneic transplantation received autologous CAR-T cells and developed chronic GVHD characterized as skin desquamation and pigmentation. Nine infections occurred in 5 patients, of which 55.6% occurred within 1 month after infusion. The overall response rate (ORR) was 80%. The complete response (CR) rate of bone marrow was 100% (7/7) and ORR of extramedullary infiltration was 40% (CR: n=1, PR: n=1). With a median follow-up of 5 months (3-14 months), PT5 with T-ALL maintained MRD-negative remission for 9 months and PT1 with mycosis fungoides achieved complete remission after low-dose local radiotherapy with no relapse to date (Figure 1). The median time of CAR-T peak expansion was 14 days after infusion (7-23 days) and the median peak numbers of CAR-T proliferation measured by flow cytometry and qPCR were 4.09x107/L (1.14x106-8.64x108/L) and 7.95x104 copies/ug DNA (2.88x102 -1.75x105 copies/ug DNA), respectively. Based on the statistical analysis with a small sample size, the peak number was not significantly correlated with the patients’ cell sources, disease subtypes, tumor burden or dose of infused cells, but was associated with the best efficacy (P=0.02). During follow-up, 50% of patients (4/8) had a relatively high level of CAR-T detected by qPCR at month 2, among whom 3 received allogeneic CAR-T cells and 1 received autologous CAR-T cells (Figure 2). Although there were no significant differences between autologous and allogeneic CAR-T cells in terms of peak expansion and clinical response at month 1, allogeneic CAR-T cells exhibited significant longer duration. Patients receiving allogeneic CAR-T have a lower recurrence rate (25% vs 100%). As for safety, the incidence of adverse events (autologous vs allogeneic, severe CRS: 20% vs 0%, GVHD: 20% vs 20%, infection in one month: 60% vs 20%) was not increased in the allogeneic CAR-T group in 1 month. However, longer duration of thrombocytopenia (median: 25 vs 18 days) and virus infections (40% vs 20%) were more common in allogeneic CAR-T group, which might lead to the death of PT9 due to cerebral hemorrhage or PT4 due to viral pneumonia. Conclusion These results indicate that anti-CD7 CAR-T is a promising option for teenager and adult patients with R/R T cell malignancies, but it is crucial to choose the source of CAR-T cells and the corresponding support treatment. Due to the higher relapse rate in patients receiving autologous CAR-T cells, we recommend consolidation therapy should be considered. For patients with allogeneic CAR-T cells, long-term monitoring and timely intervention for hemogram and infection may significantly improve patients’ outcomes. Larger sample size and longer follow-up are needed to confirm this conclusion. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI2S应助科研通管家采纳,获得10
刚刚
17应助科研通管家采纳,获得10
刚刚
dzbb应助科研通管家采纳,获得10
刚刚
najibveto应助科研通管家采纳,获得10
刚刚
赵赵a应助科研通管家采纳,获得20
刚刚
田様应助科研通管家采纳,获得10
刚刚
SciGPT应助lsx采纳,获得10
1秒前
酷波er应助jimmy采纳,获得10
1秒前
xiaofei666应助科研通管家采纳,获得30
1秒前
Keylor发布了新的文献求助10
1秒前
Lucas应助科研通管家采纳,获得10
1秒前
1秒前
华仔应助科研通管家采纳,获得10
1秒前
曲奇饼干应助科研通管家采纳,获得10
1秒前
najibveto应助科研通管家采纳,获得10
1秒前
古的古的应助科研通管家采纳,获得10
1秒前
Ava应助科研通管家采纳,获得10
1秒前
科研通AI2S应助科研通管家采纳,获得10
1秒前
薰硝壤应助科研通管家采纳,获得10
1秒前
1秒前
爆米花应助科研通管家采纳,获得10
1秒前
乐乐应助科研通管家采纳,获得10
1秒前
2秒前
happystarr完成签到,获得积分10
3秒前
典雅雨寒发布了新的文献求助10
3秒前
詹姆斯哈登完成签到,获得积分10
3秒前
Orange应助yan采纳,获得10
4秒前
小小枫叶轻轻而过完成签到,获得积分10
4秒前
4秒前
4秒前
34101127完成签到 ,获得积分10
5秒前
阮绿凝发布了新的文献求助10
6秒前
Kaysarr发布了新的文献求助10
6秒前
7秒前
jackiewang发布了新的文献求助10
7秒前
大模型应助伈X采纳,获得10
8秒前
evefei发布了新的文献求助30
8秒前
王菲爱实验完成签到,获得积分10
9秒前
9秒前
12秒前
高分求助中
Evolution 10000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 600
Distribution Dependent Stochastic Differential Equations 500
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3156964
求助须知:如何正确求助?哪些是违规求助? 2808328
关于积分的说明 7877268
捐赠科研通 2466845
什么是DOI,文献DOI怎么找? 1313040
科研通“疑难数据库(出版商)”最低求助积分说明 630355
版权声明 601919